Priority review granted for Roche's blood cancer drug in new indication

30 August 2017

Basel, Switzerland-based Roche (ROG: SIX) has been granted priority review status for its bid to broaden the label for blood cancer drug Gazyva (obinutuzumab) in the USA.

Roche has applied to extend the marketable use of the drug to include treatment in combination with chemotherapy, followed by Gazyva as a monotherapy, for people with previously untreated follicular lymphoma.

The application is supported by Phase III data comparing treatment with Rituxan (rituximab), the current standard of care. The company says the results show superior progression-free survival for its therapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK